Gene Variant Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT05211895	Phase III	Durvalumab AB154 + Durvalumab	A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8)	Recruiting	USA \| TUR \| ROU \| POL \| NOR \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BRA \| BEL	11
NCT05565417	Phase Ib/II	IMT-009	Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas	Recruiting	USA	0
NCT02019979	Phase II	Metformin	Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) (METRO)	Terminated	USA	0
NCT01712217	Phase Ib/II	Crizotinib Onalespib	A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib	Completed	USA \| FRA \| ESP \| CAN	1
NCT04266730	Phase I	PANDA-VAC + Pembrolizumab + Poly ICLC	Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (PANDA-VAC)	Not yet recruiting	USA	0
NCT02186821	Phase II	Ceritinib	Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)	Terminated	USA	0
NCT02314364	Phase II		A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC	Completed	USA	0
NCT03708328	Phase I	RO7121661	A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors	Completed	USA \| NZL \| FRA \| ESP \| DNK	1
NCT03580694	Phase I	Cemiplimab + REGN4659 Cemiplimab	Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)	Terminated	USA	0
NCT04903873	Phase Ib/II	EU101	A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors	Recruiting	USA	1
NCT04642469	Phase III	Durvalumab	Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2)	Completed	USA \| TUR \| POL \| NLD \| ITA \| ISR \| HUN \| GRC \| FRA \| ESP \| CZE \| CAN \| BRA \| BEL \| AUS \| ARG	9
NCT03906071	Phase III	Docetaxel Nivolumab + Sitravatinib	Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (SAPPHIRE)	Active, not recruiting	USA \| NLD \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BEL	0
NCT04705818	Phase II	Durvalumab + Tazemetostat	Combining Epigenetic And Immune Therapy to Beat Cancer. (CAIRE)	Recruiting	FRA	0
NCT06449313	Phase II	Cemiplimab	Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement (NEO-SURG)	Not yet recruiting	USA	0
NCT03420508	Phase II	Ensartinib	Treating Patients With Melanoma and ALK Alterations With Ensartinib	Active, not recruiting	USA	0
NCT03155620	Phase II	Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	Recruiting	USA \| CAN \| AUS	1
NCT03696212	Phase Ib/II	Grapiprant + Pembrolizumab	Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma	Terminated	USA	0
NCT03297606	Phase II	Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib	Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR)	Recruiting	CAN	0
NCT04094610	Phase Ib/II	Repotrectinib	A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations	Recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DNK \| CAN \| AUS	3
NCT01877083	Phase II	Lenvatinib	Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung	Completed	USA	4
NCT02422589	Phase I	Warfarin Midazolam Ceritinib	A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors	Completed	USA \| ITA \| ESP \| DNK	0
NCT04925986	Phase II	Pembrolizumab + Sitravatinib	Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC	Terminated	USA	0
NCT06003075	Phase II	Carboplatin + Docetaxel + Nivolumab Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel Cisplatin + Gemcitabine + Nivolumab Cisplatin + Docetaxel + Nivolumab Carboplatin + Gemcitabine + Nivolumab	Induction Chemo-Nivo in Unresectable Stage III NSCLC	Terminated	USA	0
NCT05450692	Phase III	Docetaxel Ceralasertib + Durvalumab	A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (LATIFY)	Active, not recruiting	USA \| ROU \| POL \| NLD \| ITA \| IRL \| HUN \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUS \| ARG	7
NCT05798663	Phase II	Atezolizumab Atezolizumab + Tiragolumab	Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC	Recruiting	USA	0
NCT04563338	Phase II	Atezolizumab Atezolizumab + Bevacizumab	An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)	Recruiting	CAN	0
NCT02693535	Phase II	Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)	Recruiting	USA	0
NCT05378763	Phase III	Poziotinib Docetaxel	A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations (PINNACLE)	Suspended	USA	0
NCT05221840	Phase III	Durvalumab + Oleclumab Durvalumab Durvalumab + Monalizumab	A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9)	Recruiting	USA \| TUR \| POL \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| AUS	11
NCT03166631	Phase I	BI 891065 + Ezabenlimab BI 891065	A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread	Terminated	USA	0
NCT02546986	Phase II	Azacitidine + Pembrolizumab Pembrolizumab	Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer	Active, not recruiting	USA \| ITA \| GRC \| FRA \| ESP \| DEU	0
NCT03639714	Phase Ib/II	GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab	A Study of a Personalized Neoantigen Cancer Vaccine	Completed	USA \| AUS	0
NCT04093167	Phase II	Pembrolizumab	Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC	Recruiting	USA \| CAN	0
NCT04130516	Phase Ib/II	LNS8801 LNS8801 + Pembrolizumab	Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab	Recruiting	USA	0
NCT02097810	Phase I	Entrectinib	Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. (STARTRK-1)	Completed	USA	1
NCT03213652	Phase II	Ensartinib	Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)	Recruiting	USA \| CAN \| AUS	1
NCT02892123	Phase I	Capecitabine + ZW25 ZW25 Paclitaxel + ZW25 Vinorelbine + ZW25	Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers	Active, not recruiting	USA \| CAN	1
NCT04267237	Phase II	Atezolizumab + Autogene cevumeran Atezolizumab	A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer	Withdrawn		0
NCT04622007	Phase II	Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium + Tomivosertib Pembrolizumab Pembrolizumab + Tomivosertib	Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) (KICKSTART)	Active, not recruiting	USA \| AUS	1
NCT04564157	Phase III	Carboplatin + Nivolumab + Paclitaxel Carboplatin + Paclitaxel	New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy (NADIM-ADJUVANT)	Active, not recruiting	ESP	0
NCT04524689	Phase II	Carboplatin + Pembrolizumab + Pemetrexed Disodium + SAR408701 Cisplatin + Pemetrexed Disodium + SAR408701 Carboplatin + Pembrolizumab + SAR408701 Pembrolizumab + SAR408701 Cisplatin + Pembrolizumab + SAR408701	Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05)	Active, not recruiting	USA \| ISR \| HUN \| FRA \| ESP \| CZE \| BRA	1
NCT05502237	Phase III	AB154 + Cisplatin + Pemetrexed Disodium AB154 + Carboplatin + Paclitaxel Cisplatin + Pembrolizumab + Pemetrexed Disodium AB154 + Carboplatin + Nab-paclitaxel AB154 + Carboplatin + Pemetrexed Disodium + Zimberelimab Carboplatin + Pembrolizumab + Pemetrexed Disodium AB154 + Carboplatin + Paclitaxel + Zimberelimab AB154 + Carboplatin + Nab-paclitaxel + Zimberelimab AB154 + Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab AB154 + Cisplatin + Pemetrexed Disodium + Zimberelimab	Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121)	Active, not recruiting	USA \| TUR \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUT \| ARG	9
NCT05259319	Phase I	Atezolizumab + Tiragolumab	Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) (IMMUNOs-SBRT)	Recruiting	FRA	0
NCT05403385	Phase II	Carboplatin + EOS100850 + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium	Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer	Recruiting	USA \| POL \| ITA \| GBR \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| BEL	0
NCT03175224	Phase Ib/II	Vebreltinib	APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)	Recruiting	USA \| ITA \| HUN \| GBR \| FRA \| FIN \| ESP \| CAN \| AUS	4
NCT01625234	Phase Ib/II	Ensartinib	Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer	Completed	USA	0
NCT03293680	Phase II	Pembrolizumab	Pembrolizumab in Elderly Patients With Advanced Lung Cancer	Completed	ESP	0
NCT01744652	Phase I	Crizotinib + Dasatinib	Dasatinib and Crizotinib in Advanced Cancer	Completed	USA	0
NCT01742286	Phase I	Ceritinib	Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)	Completed	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| AUS	1
NCT03003468	Phase Ib/II	Pembrolizumab + PGG beta-glucan	Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017	Completed	USA	0
NCT04609566	Phase II	Brentuximab vedotin + Pembrolizumab	Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors	Recruiting	USA \| CAN	0
NCT03138889	Phase Ib/II	NKTR-214 + Pembrolizumab Carboplatin + Nab-paclitaxel + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Paclitaxel + Pembrolizumab Cisplatin + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Pembrolizumab + Pemetrexed Disodium	Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors	Terminated	USA \| FRA \| ESP \| DEU \| AUS	0
NCT02387216	Phase II	Seribantumab Pemetrexed Disodium Docetaxel	A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC	Terminated	USA \| HUN \| FRA \| ESP \| DEU \| CAN	0
NCT03475953	Phase Ib/II	Avelumab + Regorafenib	A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE)	Recruiting	FRA	0
NCT04262856	Phase II	AB154 + Etrumadenant + Zimberelimab Zimberelimab AB154 + Zimberelimab	Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)	Active, not recruiting	USA \| CAN \| AUS	4
NCT00939770	Phase Ib/II	Crizotinib	Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	Completed	USA \| CAN	0
NCT04260802	Phase Ib/II	OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001	A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers	Recruiting	CAN	0
NCT03396497	Phase I	LYC-55716 + Pembrolizumab	Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer	Unknown status	USA	0
NCT04787042	Phase Ib/II	Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067	Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067	Active, not recruiting	USA	0
NCT03838159	Phase II	Carboplatin + Nivolumab + Paclitaxel Carboplatin + Paclitaxel	NADIM II: Neo-Adjuvant Immunotherapy (NADIMII)	Active, not recruiting	ESP	0
NCT04116541	Phase II	Alectinib Cabozantinib Ribociclib + Siremadlin	A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST)	Recruiting	FRA	0
NCT02091141	Phase II	Erlotinib Alectinib Cobimetinib + Vemurafenib Pertuzumab + Trastuzumab Vismodegib Atezolizumab	My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors	Completed	USA	0
NCT05487235	Phase I	Atezolizumab + GDC-1971 Atezolizumab + GDC-1971 + Omeprazole	A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors	Recruiting	USA \| POL \| NZL \| ESP \| CAN \| BRA \| AUS \| ARG	2
NCT01998126	Phase I	Erlotinib + Ipilimumab Crizotinib + Ipilimumab	Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts	Completed	USA	0
NCT04083976	Phase II	Erdafitinib	A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR)	Active, not recruiting	USA \| POL \| ITA \| GBR \| FRA \| ESP \| DEU \| BRA \| BEL \| AUS \| ARG	4
NCT01752400	Phase II	Luminespib	AUY922 for Advanced ALK-positive NSCLC	Completed	USA	0
NCT02289144	Phase II	Ceritinib	Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer	Withdrawn	USA	0
NCT03737994	Phase II	Cisplatin + Lorlatinib Carboplatin + Lorlatinib Ceritinib Alectinib + Cisplatin Alectinib + Carboplatin Ceritinib + Cisplatin Pemetrexed Disodium Carboplatin + Ceritinib Cisplatin + Ensartinib Carboplatin + Ensartinib Brigatinib + Cisplatin Brigatinib Alectinib Brigatinib + Carboplatin Ensartinib Cisplatin + Pemetrexed Disodium Crizotinib Carboplatin + Pemetrexed Disodium Lorlatinib	Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer	Active, not recruiting	USA	0

Gene	ALK
Variant	mutant
Impact List	unknown
Protein Effect	unknown
Gene Variant Descriptions	ALK mutant indicates an unspecified mutation in the ALK gene.
Associated Drug Resistance
Category Variants Paths

Gene Variant Detail

Contact

Filtering

Sorting

Filtering

Sorting